spacer
home > ebr > winter 2003 > editor's letter
PUBLICATIONS
European Biopharmaceutical Review

Editor's Letter

As we round up 2003, the European biotechnology sector looks ahead to 2004 with somewhat more optimism than it faced entering 2003. This appears to be the message in the marketplace, permeating numerous conference floors and news stories in recent weeks - not least the grand finale, the inaugural CORDIA-EuropaBio Convention, held in Vienna in December 2003 and reviewed later in this issue.

Whilst recent figures from Ernst & Young on European venture investment cite a decline in activity between Q2 and Q3 this year, the UK is highlighted as the exception to this negative picture potentially marking an upturn across Europe with an increase of 52 per cent


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott, Senior Consultant at Technomark Consulting Services
spacer
Dr Helen Abbott
spacer
spacer
spacer
Amy Curtis
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

The Latest Innovations in HPAPI Manufacturing Technologies

SMi’s inaugural Highly Potent Active Pharmaceutical Ingredients USA Conference, will focus on the latest innovative manufacturing technologies with a special spotlight presentation on effective and safe containment solutions for biologics based HPAPIs, along with cleaning and cross contamination requirements.
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

 
Industry Events

CPhI Korea

21-23 August 2019, COEX, Seoul, South Korea

CPhI Korea provides a dynamic meeting place for a wide range of industry suppliers to engage with purchasers and decision makers from the pharmaceutical industry in Korea and the surrounding region. The exhibition showcases the whole pharma supply chain from ingredients, contracting services to machinery and biopharmaceuticals. It also hosts an extensive conference programme covering the latest trends and topics within the regional market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement